NEW YORK, March 23, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ: SAGE). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at firstname.lastname@example.org or 212-697-6484.
This investigation concerns whether Sage and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
SAGE is a neuroscience-focused company dedicated to discovering and developing medicines to treat life-threatening, rare CNS disorders.
On March 23, 2016, Kerrisdale Capital issued a report on Sage, with allegations that its main drug, SAGE-547, designed to treat a condition called super-refractory status epilepticus ("SRSE") "is little more than a Band-Aid, achieving, at best, a temporary reduction in brain activity – very similar to many other treatments that doctors already use." Additionally, the allegations state that "Sage's estimates of the size of the SRSE market are inflated by a factor of 6," which questions the drug's commercial projections if the drug is ultimately approved.
Following this news, Sage stock dropped close to 20% during heavy intra-day trading on March 23, 2016.
If you are aware of any facts relating to this investigation, or purchased shares of Sage, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!sage/ixquo. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-sage-therapeutics-inc-sage-300240663.html
SOURCE Bronstein, Gewirtz & Grossman, LLC